Abstract
The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Keywords: proteins, hetero-oligomerization
Current Cancer Drug Targets
Title: Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents
Volume: 4 Issue: 2
Author(s): V. Gupta, D. P. Harkin, H. Kawakubo and S. Maheswaran
Affiliation:
Keywords: proteins, hetero-oligomerization
Abstract: The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
Gupta V., Harkin P. D., Kawakubo H. and Maheswaran S., Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481542
DOI https://dx.doi.org/10.2174/1568009043481542 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Efficacy of Chemopreventive Agents in Mouse Mammary Gland Organ Culture (MMOC) Model: A Comprehensive Review
Current Medicinal Chemistry PPARγ: Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism
Current Drug Targets The Application of X-ray, NMR, and Molecular Modeling in the Design of MMP Inhibitors
Current Topics in Medicinal Chemistry Cardiovascular Risk Factors: Does Sex Matter?
Current Vascular Pharmacology Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Molecular Approach to Targeted Therapy for Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Dual Antibacterial and Anticancer Activity of 4-Benzoyl-1-dichlorobenzoylthiosemicarbazide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Magnetic Nanoparticles for Cancer Therapy
Current Nanoscience Ellipticines as DNA-Targeted Chemotherapeutics
Current Medicinal Chemistry Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Editorial [Hot Topic: Anti-Lipogenesis as a Novel Strategy for Cancer Therapy (Guest Editors: Jianghua Liu and Deliang Cao)]
Recent Patents on Anti-Cancer Drug Discovery Editorial [Hot Topic: Molecular Imaging in Current Pharmaceuticals (Guest Editor: Ramasamy Paulmurugan)]
Current Pharmaceutical Biotechnology Triple Negative Breast Cancer: A Review
Current Women`s Health Reviews Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Knee Meniscus Segmentation and Tear Detection from MRI: A Review
Current Medical Imaging Malignant Phyllodes Tumors with Heterologous Sarcomatous Elements Presenting as Hyperechoic Masses on Ultrasonography: A Case Report
Current Medical Imaging Preparation, Characterization and <i>In Vitro</i> Biological Evaluation of Novel Curcumin Derivatives as Cytotoxic and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry